搜尋結果
2024年5月20日 · BURLINGTON, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), presented new data from its preclinical Rejuva pancreatic gene therapy program as part of an oral presentation (abstr...
2024年5月2日 · Inaugural international clinical advisory board to provide strategic guidance towards development of the company’s ERES endoscopic robot SINGAPORE, May 2, 2024 /PRNewswire/ — Vivo Surgical Private Limited, a privately-held surgical technology company pioneering a flexible endoscopic robot for advanced endoscopic resections, is excited to unveil its inaugural International Clinical Advisory ...
2024年5月2日 · HOUSTON, May 2, 2024 /PRNewswire/ — United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) with the clearance of its uMR Jupiter 5T MRI system.
2024年4月26日 · Medical director and co-founder of BioMed, Dr. Steven Loo stated, “We are honored to be the first company to receive investment from the newly established CUHK Innovation Limited. This partnership will provide us with invaluable support and access to CUHK’s robust ecosystem, enabling us to accelerate our research and development initiatives and expand our market presence.
2024年5月11日 · KFSH&RC 透過全基因組測序 (whole-genome sequencing, WGS) 技術，發現了 Stenotrophomonas Riyadhensis 菌株，有助於我們了解細菌對抗生素的抗藥性機理。. 2023 年，中心共接待 15,698 名病人，完成逾 5,658 項全基因組測序，確保預防、診斷及治療都能精準針對個人。. KFSH&RC 的 ...
2024年5月14日 · BASEL, Switzerland – 14th May 2024 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces today that Neil Gallagher, MD, PhD, has been appointed as an Independent Advisor to Nouscom’s Board of Directors and will also Chair the Company’s R&D...
6 天前 · SAN FRANCISCO, May 21, 2024 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced an oversubscribed Series B financing of up to $225 million.
